Stopped: PI left organization and discontinued study
This study will be performed to evaluate the Clinical Outcomes and Quality of Life after Transarterial Radioembolization with Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults with Liver Tumors. The treatment and techniques used here are well established in adults. The purpose of this study is to evaluate: 1. the response to treatment and clinical outcomes of treatment with TARE Y-90 as part of standard therapy and 2. to assess the change in the patient's quality of life before, during and after treatment with TARE-Y90
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Determine the impact of TARE-Y90 treatment on health related quality of life (HRQOL)
Timeframe: Assessed at baseline/time of treatment
Determine the impact of TARE-Y90 treatment on health related quality of life (HRQOL)
Timeframe: Assessed at 1 month post therapy
Determine the impact of TARE-Y90 treatment on health related quality of life (HRQOL)
Timeframe: Assessed at 6 months post therapy
Determine the impact of TARE-Y90 treatment on health related quality of life (HRQOL)
Timeframe: Assessed at 12 months post therapy
Determine the impact of TARE-Y90 treatment on health related quality of life (HRQOL)
Timeframe: Assessed at 5 years post therapy
Evaluate the efficacy and clinical utility of TARE-Y90 by examining 2 year survival
Timeframe: Patients will be assessed at 2 years post therapy
Evaluate the efficacy and clinical utility of TARE-Y90 by examining 5 year survival
Timeframe: Patients will be assessed at 5 years post therapy
Evaluate the efficacy and clinical utility of TARE-Y90 by examining local tumor response
Timeframe: Patients will be assessed at the end of treatment which is typically 2-4 months following treatment
Evaluate the efficacy and clinical utility of TARE-Y90 by examining resection rate
Timeframe: Patients will be assessed at the end of treatment which is typically 2-4 months following treatment.
Evaluate the efficacy and clinical utility of TARE-Y90 by examining Transplant rate
Timeframe: Patients will be assessed at the end of treatment which is typically 2-4 months following treatment.
Evaluate the efficacy and clinical utility of TARE-Y90 by examining histologic response
Timeframe: Patients will be assessed at the end of treatment which is typically 2-4 months following treatment.
Evaluate the efficacy and clinical utility of TARE-Y90 by examining biologic response
Timeframe: Patients will be assessed at the end of treatment which is typically 2-4 months following treatment.
Evaluate the efficacy and clinical utility of TARE-Y90 by examining clinical course
Timeframe: Patients will be assessed at the end of treatment which is typically 2-4 months following treatment.